Otsuka Pharmaceutical Companies (U.S.)

Otsuka Pharmaceutical Companies (U.S.)

Pharmaceutical Manufacturing

Princeton, NJ 189,043 followers

Creating new products for better health worldwide.

About us

There are two Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.

Website
http://www.otsuka-us.com
Industry
Pharmaceutical Manufacturing
Company size
1,001-5,000 employees
Headquarters
Princeton, NJ
Type
Privately Held
Specialties
Neuroscience

Locations

Employees at Otsuka Pharmaceutical Companies (U.S.)

Updates

  • Our InTOW cohort told us #WhyOtsuka. Take a look at some of their responses.    Otsuka is a healthcare company comprised of motivated individuals we call Otsuka-people—people who have a shared mission for creating new products for better health worldwide.   We live by our purpose: defy limitation, so that others can too. This purpose gives meaning to our work and motivates us each day.    Learn more about our culture now: https://bit.ly/3YsWOlg #DefyLimitation

  • In honor of the 16th anniversary of the codification of the Six Protected Classes policy, we are excited to share an op-ed by a member of the Partnership for Part D Access Clinician Advisory Board, Roaya Tyson, CEO of Gracepoint Wellness. As a member of the Partnership, Otsuka supports the vital role of maintaining the 6PC policy, amidst rising healthcare costs and a complex health system, as a top priority in the Part D space. It is our privilege to walk alongside our communities as allies and advocates to overcome barriers and reduce inequities. Our promise is to invest in products, programs, policies, and advocacy efforts that help remove stigma and discrimination, increase access to care, and address social determinants of health. This is not just our promise, it is our passion.

    Medicare’s Protected Drug Classes: A Legacy in Need of Defending

    Medicare’s Protected Drug Classes: A Legacy in Need of Defending

    medium.com

  • Looking for an exciting chance to enter the pharmaceutical industry? We are actively recruiting Health Science Advisors for our unique 18-month ReadyNow program. No traditional sales experience needed—just the right mindset and skills to support our CNS (central nervous systems) Sales Team. New hires will be supported by the ReadyNow leadership team, trusted advisors, and field leaders. We seek candidates who:  - Are effective communicators  - Demonstrate grit, drive and accountability for results   - Have a growth mindset with a desire to learn and be coachable  - Possess strategic thinking and problem-solving abilities    Do you or someone you know who fit this description? We’d love to meet you. Check out the listing: https://bit.ly/3WFF7N2

  • At Otsuka, putting our patients and communities first is at the heart of all we do. With this mission in mind, we proudly support Clubhouse International , a nonprofit focused on ending social and economic isolation for those living with mental illness, in a multi-year commitment.  With more than 360 Clubhouses in 33 countries, this commitment supports the Clubhouse International Intensive Employee Support program, helping Clubhouse International expand its employment support so more Clubhouse members gain and maintain employment. To date, we've proudly helped strengthen employment outcomes at 97 Clubhouses and are committed to ongoing support through our funding and additional support beyond dollars.  At Otsuka, we hold a deep respect for the value of every mind. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention for patients everywhere.  For more on our Social Impact work: https://lnkd.in/g7RbkydN

  • Driven by our purpose to defy limitation and our mission to create new products for better health worldwide, we believe in the value of every mind and will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention for patients and caregivers everywhere.    This National Wellness Month, we continue to uphold our commitment to putting the health and safety of patients first and finding unconventional solutions for the unmet medical needs of underserved communities.     Discover our commitment to health for every mind: https://bit.ly/4c2fZpq

  • “Agitation is one of the most complex and stressful aspects of caring for people living with Alzheimer's dementia,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka. Today, we are pleased to present, in collaboration with Lundbeck, the results from the new post hoc pooled analyses of Phase 3 trials evaluating the safety and efficacy for the treatment in patients with agitation associated with dementia due to Alzheimer’s disease. We are committed to persevere until mental health and brain diseases are approached with the same priority and urgency as physical health. Read more here: https://bit.ly/3YqnCCI #DefyLimitation

  • Meet Ty.   Ty is a sandwich generation caregiver to her mother, Gertrude.   Half (50%) of the sandwich generation caregivers that are caring for a loved one with Alzheimer’s disease or dementia report that they feel unprepared for the role.   As Ty raises her children, she navigates the intricacies of the caregiving journey that many are all too familiar with. Ty’s strength and resilience pushed her to find joy in difficult circumstances, and we are emotional hearing her powerful story.  Watch the latest installment of Still Here: Caregiver Conversations out now - https://bit.ly/4ditD9r   Ty is a paid collaborator of Otsuka America Pharmaceutical, Inc.

  • Earlier this summer, we were humbled to be part of the first annual Stop Stigma Together (SST) summit to end the stigma against mental illness and substance use disorder. As part of our participation, we had the opportunity to share the findings from ‘The Projected Cost and Economic Impact of Mental Health Inequities in the United States report,’ authored by national expert Daniel Dawes, Dean of the Meharry School of Global Health with fellow attendees. Through our commitment to health for every mind, we will continue to emphasize that the mental health crisis in the United States should be treated as an emergency, encompassing a cross-sector approach. To read the full report: https://bit.ly/4dybF30 Otsuka is proud to be a lead, founding sponsor of 'The Projected Cost and Economic Impact of Mental Health Inequities in the United States Report.’

Similar pages

Browse jobs